Drug intelligence / Profile preview

salfaprodil

Development stage: Phase 3
Lead developer: GNT Pharma
Modality: Small Molecules
Administration: Intravenous

Overview

Salfaprodil is a small molecule neuroprotectant that acts as an NR2B-selective and uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the NR2B subunit. It also functions as a free radical scavenger, providing antioxidant effects. Salfaprodil has been developed primarily for acute ischemic stroke and has demonstrated neuroprotection in preclinical models of cerebral ischemia/reperfusion injury. The drug is administered intravenously and is considered a first-in-class dual neuroprotectant due to its combined NMDA antagonism and antioxidant properties[3][4][5].

Brand names: Nelonemdaz
Other names: salfaprodilnelonemdaz potassiumnelonemdaz (potassium)nelonemdaz potassium salt

Targets

GRIN2B (N-methyl-D-aspartate Receptor Subunit Combination: NR1a/NR2B)

Beyond the preview

Go deeper on salfaprodil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on salfaprodil.

Explore the full profile